Serono/Pfizer Rebif Will Reach 30% Share By 2006, Serono Says
Executive Summary
Serono is increasing its market share projection for the multiple sclerosis agent Rebif by at least five percentage points in light of its co-promotion agreement with Pfizer
You may also be interested in...
Serono Rebif: 80% Of Rxs Are Switches, Efficacy Is Main Marketing Message
Eighty percent of Rebif prescriptions are switches away from other multiple sclerosis therapies, Serono VP-Neurology Corporate Marketing Samar Shah, MD, said during Serono's R&D day in London Dec. 2
Serono Rebif: 80% Of Rxs Are Switches, Efficacy Is Main Marketing Message
Eighty percent of Rebif prescriptions are switches away from other multiple sclerosis therapies, Serono VP-Neurology Corporate Marketing Samar Shah, MD, said during Serono's R&D day in London Dec. 2
Serono/Pfizer Rebif Co-Promotion Deal Will Use Neurontin Sales Force
Pfizer's Neurontin sales force will co-promote Serono's multiple sclerosis drug Rebif under an agreement announced by the two companies July 11